Department of Clinical Pharmacology, Fortis Hospital Mohali, Mohali, India.
Department of Pharmacology, University College of Medical Sciences, Delhi, India.
J Basic Clin Physiol Pharmacol. 2022 Jan 7;33(1):103-107. doi: 10.1515/jbcpp-2021-0221.
The use of Hydroxychloroquine (HCQ) prophylaxis has been recommended by the National task force constituted by the Indian Council of Medical Research (ICMR) for the prevention of corona virus disease 2019 (COVID-19) among healthcare workers (HCWs). However, this recommendation was based essentially on the preclinical data and limited clinical experience. The aim of this study was to evaluate the efficacy and safety of HCQ as a pre-exposure prophylaxis for COVID-19 infection among Indian HCWs.
A cross-sectional study was conducted among HCWs of a tertiary care hospital in north India. The HCQ prophylaxis was initiated among 996 HCWs and they were followed up to 8 weeks for conversion to COVID-19 positive status and any adverse drug reaction (ADR).
About 10.3% of the study participants were tested positive for COVID-19 which was comparable to the positivity rate among HCWs not taking HCQ prophylaxis (9.7%).
HCQ was well tolerated at a weekly dose of 400 mg for 8 weeks but provided no additional benefit in prevention of COVID-19 among HCWs.
印度医学研究理事会（ICMR）成立的国家工作队建议使用羟氯喹（HCQ）预防用于预防医护人员（HCWs）的 2019 年冠状病毒病（COVID-19）。但是，该建议主要基于临床前数据和有限的临床经验。本研究旨在评估 HCQ 作为印度 HCWs COVID-19 感染暴露前预防的疗效和安全性。
在印度北部的一家三级保健医院进行了一项横断面研究。在 996 名 HCWs 中启动了 HCQ 预防，并对他们进行了 8 周的随访，以了解转为 COVID-19 阳性状态和任何药物不良反应（ADR）的情况。
约 10.3%的研究参与者 COVID-19 检测呈阳性，与未服用 HCQ 预防药物的 HCWs 的阳性率（9.7%）相当。
HCQ 每周 400mg 服用 8 周耐受性良好，但不能为 HCWs 预防 COVID-19 提供额外益处。
